STAT+: A deep dive into Eli Lilly’s tantalizing Alzheimer’s drug data

Here is some analysis and perspective, not to mention a few burning questions, about the Phase 2 data Eli Lilly disclosed on its experimental Alzheimer’s therapy donanemab on Saturday. 

STAT earlier asked five independent scientists involved in Alzheimer’s research about the study; unsurprisingly, their opinions were quite mixed, with the data representing a Rorschah test for their views on Alzheimer’s drug development. The study was also published in the New England Journal of Medicine.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: A deep dive into Eli Lilly’s tantalizing Alzheimer’s drug data »